| Abstrakt: |
Researchers at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia, have conducted a study on redifferentiation therapies in thyroid oncology, focusing on molecular and clinical aspects. The study highlights the use of alternative treatments, such as tyrosine kinase inhibitors, for patients with radioiodine-refractory differentiated thyroid cancer. By targeting the MAPK pathway, these therapies aim to restore radioiodine sensitivity in previously refractory patients, potentially improving the efficacy of radioiodine therapy. The research provides insights into various redifferentiation strategies and their implications for clinical practice. [Extracted from the article] |
